6400
M. Arthuis et al. / Tetrahedron Letters 48 (2007) 6397–6400
isomerize to the (Z)-isomeric forms, which does not inhibit
tubulin polymerization. See: (a) Andreani, A.; Burnelli, S.;
Granaiola, M.; Leoni, A.; Locatelli, A.; Morigi, R.;
Rambaldi, M.; Varoli, L.; Kunkel, M. W. J. Med. Chem.
2006, 49, 6922–6924; (b) Pandit, B.; Sun, Y.; Chen, P.;
Sackett, D. L.; Hu, Z.; Rich, W.; Li, C.; Lewis, A.; Schaefer,
K.; Li, P.-K. Bioorg. Med. Chem. 2006, 14, 6492–6501.
17. Ducki, S.; Forrest, R.; Hadfield, J. A.; Kendall, A.;
Lawrence, N. J.; McGown, A. T.; Rennison, D. Bioorg.
Med. Chem. Lett. 1998, 8, 1051–1056.
biological evaluation. Expansion of this work to the syn-
thesis of derivatives with other heterocyclic cores is in
progress.
Acknowledgements
The authors are pleased to thank C. Meyer and S. Couty
(UMR 7084, CNRS/ESPCI, Paris) for helpful discus-
sions. This work was financially supported by CNRS
18. Hadfield, J. A.; Gaukroger, K.; Hirst, N.; Weston, A. P.;
Lawrence, N. J.; McGown, A. T. Eur. J. Med. Chem.
2005, 40, 529–541.
`
and Institut Curie. M.A. thanks the Ministere de l’Ens-
´
eignement Superieur et de la Recherche for a PhD Fel-
19. Representative experimental procedure: synthesis of 1-benz-
yl-3-[3-(30,40,50-trimethoxyphenyl)allylidene]indolin-2-one
IIe (entry 4): To a stirred solution of alkyneamide 4e
(80 mg, 0.221 mmol) in dry THF (12 mL) were added (E)-
2-(30,40,50-trimethoxyphenyl)vinylboronic acid 6 (58 mg,
0.243 mmol) and CsF (100 mg, 0.663 mmol). The resulting
mixture was degassed (argon bubbling, 15 min) then PPh3
(5.8 mg, 0.022 mmol) and Pd(OAc)2 (2.5 mg, 0.011 mmol)
were added. After heating at reflux for 2 h, the reaction
was cooled to rt, quenched with distilled water and
extracted with diethylether (twice). The combined organic
extracts were washed with brine, dried over MgSO4,
filtered and concentrated in vacuo. The resultant crude
product was purified by column chromatography on silica
gel (cyclohexane/EtOAc: 8/2) to give successively (EZ)-IIe
as an orange oil (2 mg) and (EE)-IIe (52 mg) as a pale
orange crystalline solid (global yield: 55%) (EZ)-IIe: 1H
NMR (300 MHz, CDCl3) d 8.54 (dd, J = 15.6, 11.5 Hz,
1H, H-b), 7.46 (d, J = 7.4 Hz, 1H, H-4), 7.33 (d,
J = 11.5 Hz, 1H, H-c), 7.32–7.26 (m, 5H, H-Ph), 7.14
(td, J = 7.6, 1.0 Hz, 1H, H-6), 7.00 (td, J = 7.6, 1.0 Hz,
1H, H-5), 6.97 (d, J = 15.6 Hz, 1H), 6.83 (s, 2H, H-20,60),
6.70 (d, J = 7.6 Hz, 1H, H-7), 4.98 (s, 2H, CH2), 3.91 (s,
6H, OCH3 · 2), 3.88 (s, 3H, OCH3); 13C NMR (75 MHz,
CDCl3) d 167.5 (C), 153.4 (C · 2), 143.3 (CH-a), 141.6 (C),
139.5 (C), 136.4 (CH-c), 136.2 (C), 132.0 (C), 128.7
(CH · 2), 128.6 (CH), 127.5 (CH), 127.2 (CH · 2), 124.0
(CH-b), 123.9 (C), 123.5 (C), 121.9 (CH), 119.2 (CH),
108.9 (CH), 104.9 (CH · 2), 61.0 (CH3), 56.2 (CH3 · 2),
43.3 (CH2); ESI+-MS: m/z = 428 [M+H]+, 450 [M+Na]+,
466 [M+K]+. (EE)-IIe: orange crystals, mp 195 ꢁC; 1H
NMR (300 MHz, CDCl3) d 7.68 (d, J = 7.6 Hz, 1H, H-4),
7.58–7.47 (m, 2H, H-b, H-c), 7.32–7.26 (m, 5H, H-Ph),
7.17 (td, J = 7.6, 1.4 Hz, 1H, H-6); 7.10 (d, J = 14.5, 1H,
H-a), 7.05 (td, J = 7.6, 1.0 Hz, H-5), 6.80 (s, 2H, H-20,60),
6.74 (d, J = 7.6 Hz, 1H, H-7), 4.98 (s, 2H, CH2), 3.94 (s,
6H, OCH3 · 2), 3.90 (s, 3H, OCH3). 13C NMR (75 MHz,
CDCl3) d 168.7 (C), 153.5 (C · 2), 144.4 (CH-a), 142.7 (C),
139.9 (C), 136.1 (CH-c), 136.0 (C), 131.7 (C), 128.8 (CH),
128.7 (CH · 2), 127.5 (CH), 127.2 (CH · 2), 124.8 (C),
123.2 (CH), 122.8 (CH-b), 122.5 (C), 122.0 (CH), 109.2
(CH), 104.9 (CH · 2), 61.0 (CH3), 56.3 (CH3 · 2), 43.7
(CH2). HRMS (DCI-NH3): m/z calcd for C27H26O4N
[M+H]+: 428.1862; found: 428.1852.
lowship Grant.
References and notes
1. Lippert, J. W., III. Bioorg. Med. Chem. 2007, 15, 605–615,
and references cited therein.
2. For reviews on CA4 analogues, see: (a) Tron, G. C.; Pirali,
T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A. J.
Med. Chem. 2006, 49, 3033–3044; (b) Hseih, H. P.; Liou, J.
P.; Mahindroo, N. Curr. Pharm. Des. 2005, 1655–1677.
3. Kaffy, J.; Pontikis, R.; Florent, J. C.; Monneret, C. Org.
Biomol. Chem. 2005, 5, 2657–2660.
4. Burns, B.; Grigg, R.; Sridharan, V.; Stevenson, P.;
Sukirthalingam, S.; Worakun, T. Tetrahedron Lett. 1989,
30, 1135–1138.
5. Oh, C. H.; Lim, Y. M. Tetrahedron Lett. 2003, 44, 267–
270.
6. Min, S.-H.; Pang, S.-J.; Cho, C.-G. Tetrahedron Lett.
2003, 44, 4439–4442.
´
7. Couty, S.; Liegault, B.; Meyer, C.; Cossy, J. Org. Lett.
2004, 6, 2511–2514.
8. Cheung, W. S.; Patch, R. J.; Player, M. R. J. Org. Chem.
2005, 70, 3741–3744.
9. Yanada, R.; Obika, S.; Inokuma, T.; Yanada, K.;
Yamashita, M.; Ohta, S.; Takemoto, Y. J. Org. Chem.
2005, 70, 6972–6975.
10. An analogous tandem process was recently reported by a
rhodium-catalysis. See: Shintani, R.; Yamagami, T.;
Hayashi, T. Org. Lett. 2006, 8, 4799–4801.
11. (a) Yamada, H.; Aoyagi, S.; Kibayashi, C. Tetrahedron
Lett. 1997, 38, 3027–3030; For a review on carbopallada-
´
tion, see: (b) Negishi, E.; Coperet, C.; Ma, S.; Liou, S.-Y.;
Liu, F. Chem. Rev. 1996, 96, 365–393.
12. For the desired CA4 analogues of type II, stereochemistry
would be trans for the double bond Ca–Cb and cis for the
exocyclic one. This corresponds to the configuration (EE)
for the oxindole derivatives.
13. Alkynamides 4a, 4b and 4e have already been reported, 4a
and 4b being synthesized by acylation of 7a with the
methyl ester of 8a or 8b. See: Yanada, R.; Obika, S.;
Kobayashi, Y.; Inokuma, T.; Oyama, M.; Yanada, K.;
Takemoto, Y. Adv. Synth. Catal. 2005, 347, 1632–1642.
14. Brunton, S. A.; Jones, K. J. Chem. Soc., Perkin Trans. 1
2000, 763–768.
20. Teichert, A.; Jantos, K.; Harms, K.; Studer, A. Org. Lett.
2004, 6, 3477–3480.
15. Ma, C.; Liu, X.; Li, X.; Flippen-Anderson, J.; Yu, S.;
Cook, J. M. J. Org. Chem. 2001, 66, 4525–4542.
16. Several 3-trimethoxybenzylidene oxindoles with the (E)-
configuration were obtained by coupling trimethoxybenz-
aldehyde and the appropriate indolinone in the presence of
piperidine. But these derivatives are reported to gradually
21. Sun, L.; Tran, N.; Tang, F.; App, H.; Hirth, P.; McMa-
hon, G.; Tang, C. J. Med. Chem. 1998, 41, 2588–2603.
22. For compound (EZ)-IIb, a positive NOE was observed
between the methyl substituent of the exocyclic double
bond and the aromatic proton in the 4-position of the
indole core.